{"id":4473,"date":"2026-10-07T08:17:39","date_gmt":"2026-10-07T02:47:39","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/lupin-share-price-today-2026-10-07\/"},"modified":"2026-10-07T17:32:34","modified_gmt":"2026-10-07T12:02:34","slug":"lupin-share-price-today-2026-10-07","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/lupin-share-price-today-2026-10-07\/","title":{"rendered":"LUPIN Share Price Today: Why LUPIN Is Falling 0.81% | 7 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: LUPIN<\/strong> \u00b7 7 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b92,012.90<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>-0.81%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b92,030.00 \/ \u20b92,001.60<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b92,029.30<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>7.85 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>7 October 2026 \u00b7 03:15 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Lupin Limited shares moved lower today, trading down by 0.81% to close at \u20b92012.90 compared to the previous close of \u20b92029.30. The stock moved within a daily range of \u20b92001.60 and \u20b92030.00, opening slightly lower at \u20b92028.30.<\/li>\n<li>Lupin announced the commercial launch of Formoflo-G\u00ae MDI in India following approval from the Drug Controller General of India. It is positioned as the world&#x27;s first fixed-dose triple combination metered-dose inhaler combining Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate for moderate to severe COPD. The therapy targets an estimated 55 million COPD patients in India, strengthening the company&#x27;s established #2 ranking in the domestic respiratory segment.<\/li>\n<li>Trading volume was 1.18 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is LUPIN share price falling on 7 October 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Lupin Limited shares moved lower today, trading down by 0.81% to close at \u20b92012.90 compared to the previous close of \u20b92029.30. The stock moved within a daily range of \u20b92001.60 and \u20b92030.00, opening slightly lower at \u20b92028.30.<\/p>\n<p class=\"wt-copy\">The broader market exhibited negative momentum, with the benchmark Nifty declining by 0.76%. Sector performance was similarly subdued, as the Nifty Pharma index slipped 0.43%. Lupin&#x27;s modest decline sits in line with the broader sector correction and general market weakness, while short-term returns show a 5-day decline of 1.91% and a 20-day drawdown of 4.36%.<\/p>\n<p class=\"wt-copy\">Company-specific news flow includes a recent press release dated October 06, 2026, announcing the launch of Formoflo-G\u00ae MDI in India, recognized as the world&#x27;s first fixed-dose triple combination drug for COPD management following DCGI approval. Additional recent developments include a tentative U.S. FDA approval for Apixaban Oral Suspension on September 28, 2026, and full ownership consolidation of Multicare Pharmaceuticals Philippines effective October 01, 2026. However, these operational updates did not provide an immediate upward catalyst, as the stock drifted lower alongside broader pharmaceutical and market indices.<\/p>\n<p class=\"wt-copy\">7.85 lakh shares traded by 7 October 2026 \u00b7 03:15 PM IST. This compares with a 20-day average daily volume of 6.66 lakh shares (1.18 times). The five-day average daily volume was 8.98 lakh shares. Separately, the NSE report for 6 October 2026 showed 7.38 lakh shares delivered, representing 69.19% of that day\u2019s traded volume. The same report recorded 46,799 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>sector-aligned pullback and mild profit-taking<\/strong><\/p>\n<p class=\"wt-copy\">The 0.81% decline in Lupin shares lacks a direct negative company catalyst and appears consistent with general market weakness and minor profit-taking following recent consolidation. Broader sector benchmarks also traded lower, aligning the stock&#x27;s movement with the Nifty Pharma trend.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Launch of Formoflo-G\u00ae MDI for COPD Management<\/div>\n<div class=\"wt-card-date\">6 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Lupin announced the commercial launch of Formoflo-G\u00ae MDI in India following approval from the Drug Controller General of India. It is positioned as the world&#x27;s first fixed-dose triple combination metered-dose inhaler combining Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate for moderate to severe COPD. The therapy targets an estimated 55 million COPD patients in India, strengthening the company&#x27;s established #2 ranking in the domestic respiratory segment.<\/p>\n<p class=\"wt-copy\">Expands Lupin&#x27;s domestic specialty portfolio in a core chronic therapeutic area.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_06102026093541_SELetterpressrelease.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Tentative U.S. FDA Approval for Apixaban Oral Suspension<\/div>\n<div class=\"wt-card-date\">28 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Lupin received tentative approval from the U.S. FDA for its New Drug Application for Apixaban Oral Suspension 1.25 mg\/mL under the 505(b)(2) pathway. The product serves as an alternative oral liquid formulation to Bristol Myers Squibb&#x27;s Eliquis\u00ae, designed for adult patients requiring anticoagulation therapy who have difficulty swallowing tablets. Upon final approval, manufacturing will be handled at the company&#x27;s Somerset, New Jersey facility.<\/p>\n<p class=\"wt-copy\">Strengthens the U.S. specialty pipeline with a differentiated patient-centric formulation.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_28092026091311_SELetterPressRelease.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Completion of Subsidiary Buyback in the Philippines<\/div>\n<div class=\"wt-card-date\">1 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Multicare Pharmaceuticals Philippines, Inc. completed the buyback of 30,559 shares, concluding a process initiated earlier in July 2026. Following the transaction, Multicare became a wholly owned subsidiary of Nanomi B.V. and a step-down wholly owned subsidiary of Lupin Limited effective October 01, 2026. This administrative consolidation simplifies the regional corporate structure.<\/p>\n<p class=\"wt-copy\">Deepens operational ownership and control within the Southeast Asian regional footprint.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_01102026100316_SE_intimation_of_Buyback_completion.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Press Release<\/div>\n<div class=\"wt-card-date\">6 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated October 06, 2026, titled &quot;Lupin Launches Formoflo-G\u00ae MDI, World s First Fixed-dose Triple Combination Drug for COPD Management&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_06102026093541_SELetterpressrelease.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Earnings \/ operating update<\/div>\n<div class=\"wt-card-date\">7 August 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated August 06, 2026, titled &quot;Lupin Q1 FY2027 Results &quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_06082026215741_SE_Intimation_Press_Release.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 June 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">46.85%<\/div>\n<div class=\"wt-note\">46.86% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">22.42%<\/div>\n<div class=\"wt-note\">21.71% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">47.07%<\/div>\n<div class=\"wt-note\">47.03% on 31 March 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1698021_21072026020405_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 14.84% on 30 June 2026. This compares with 16.93% on 31 March 2026, a change of -2.09 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 39 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Hdfc Trustee Company Ltd. A\/C Hdfc Balanced Advantage Fund<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">2.00 crore shares \u00b7 4.37%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Nippon Life India Trustee Ltd- A\/C Nippon India Growth Mid Cap Fund<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">1.19 crore shares \u00b7 2.60%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Sbi Elss Tax Saver Fund<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">89.59 lakh shares \u00b7 1.96%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1698021_21072026020405_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Historical Bulk \/ Block Deals<\/h2>\n<div class=\"wt-grid wt-grid-cards\">\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">Block<\/div>\n<div class=\"wt-card-date\">27 August 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Price Action | Lupin shares slip as Citi downgrades to sell; ICICI Pru AMC slips 3% on block deal. Price Action | Lupin shares slip as Citi downgrades to sell; ICICI Pru AMC slips 3% on block deal Moneycontrol.com<\/p>\n<div class=\"wt-note wt-source-note\">Moneycontrol.com<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Execution and market uptake of the newly launched Formoflo-G\u00ae MDI in the Indian respiratory segment<\/li>\n<li>Final U.S. FDA approval timelines for Apixaban Oral Suspension from the Somerset facility<\/li>\n<li>Volume trends and cash delivery percentages relative to the 20-day average volume baseline<\/li>\n<li>Performance of the Nifty Pharma index and broader market risk sentiment<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/lupin-share-price-today-2026-10-06\/\">Why Lupin Shares Are Rising 0.91% Today With Sector Tailwinds | 6 October 2026 \u2014 6 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/lupin\/\">More LUPIN news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest LUPIN company news?<\/h3>\n<p class=\"wt-copy\">Lupin announced the commercial launch of Formoflo-G\u00ae MDI in India following approval from the Drug Controller General of India. It is positioned as the world&#x27;s first fixed-dose triple combination metered-dose inhaler combining Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate for moderate to severe COPD. The therapy targets an estimated 55 million COPD patients in India, strengthening the company&#x27;s established #2 ranking in the domestic respiratory segment.<\/p>\n<h3>How strong was LUPIN\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">7.85 lakh shares traded, 1.18 times the 20-day average daily volume. The price and volume data are dated 7 October 2026 \u00b7 03:15 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/lupin-share-price-today-2026-10-07\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/lupin-share-price-today-2026-10-07\/\"}, \"headline\": \"LUPIN Share Price Today: Why LUPIN Is Falling 0.81% | 7 October 2026\", \"description\": \"LUPIN share price fell 0.81% to \u20b92,012.90 today. See why LUPIN is falling, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-10-07T02:47:39Z\", \"dateModified\": \"2026-10-07T17:32:23.939340+05:30\", \"author\": {\"@type\": \"Organization\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"reviewedBy\": {\"@type\": \"Person\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"WittyTrades\", \"url\": \"https:\/\/www.wittytrades.com\/\"}, \"inLanguage\": \"en-IN\", \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/lupin-company-news-2026-10-07.jpg\"]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Press Release\",\"summary\":\"a press release dated October 06, 2026, titled \\\"Lupin Launches Formoflo-G\u00ae MDI, World s First Fixed-dose Triple Combination Drug for COPD Management\\\".\",\"source\":\"NSE\",\"published\":\"06-Oct-2026 09:38:12\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_06102026093541_SELetterpressrelease.pdf\",\"disclosure_text\":\"LUPIN LIMITED Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 info@lupin.com | www.lupin.com October 06, 2026 National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 BSE Limited P. J. Towers, Dalal Street, Mumbai Samachar Marg, Mumbai - 400 001 Symbol: LUPIN Scrip Code: Equity - 500257 Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir\/Madam, We are pleased to enclose a Press Release titled \u201cLupin Launches Formoflo-G\u00ae MDI, World\u2019s First Fixed -dose Triple Combination Drug for COPD Management\u201d. The same is for your information and dissemination. Thanking you, For LUPIN LIMITED AMIT KUMAR GUPTA COMPANY SECRETARY & COMPLIANCE OFFICER (ACS -15754) Encl.: a\/a. Page 1 of 2 BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN Press Release Lupin Launches Formoflo-G\u00ae MDI, World\u2019s First Fixed-dose Triple Combination Drug for COPD Management Mumbai, October 6, 2026: Lupin Limited (Lupin) has launched Formoflo-G\u00ae MDI, the world's first fixed- dose triple combination metered-dose inhaler (MDI) for chronic obstructive pulmonary disease (COPD) in India, following approval from the Drug Controller General of India (DCGI). The launch marks a significant advancement in respiratory care, expanding treatment options for patients living with COPD. Lupin Formoflo-G\u00ae is a first-of-its-kind MDI that combines Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate for the long-term management and treatment of moderate to severe COPD. The product is available as a twice-daily, single-strength fixed dose, bringing hope to more than 55 million people living with COPD in India, a condition that remains a leading cause of death and disability. Commenting on the launch, Nilesh Gupta, Managing Director, Lupin , said, \\\"As respiratory diseases continue to impact millions across India, access to effective therapies remains critical. Formoflo-G\u00ae MDI reflects our commitment to addressing unmet patient needs through differentiated, high-quality therapies. By combining innovation with accessibility, we aim to improve outcomes for patients living with respiratory diseases.\\\" Rajeev Sibal, President \u2013 India Region Formulations, Lupin , said, \u201cFormoflo-G\u00ae MDI marks an important addition to our respiratory portfolio, bringing together three established therapies in a single inhaler. It strengthens Lupin\u2019s respiratory portfolio and provides healthcare professionals with an important treatment option for appropriate COPD patients. It reflects our commitment to delivering innovative, high-quality therapies that help improve patient outcomes.\\\" Ranked #2 in the respiratory therapy segment in India ( IQVIA, MAT Mar 2026 ), Lupin continues to strengthen its leadership in respiratory care with the launch of Formoflo-G\u00ae MDI, reinforcing its focus on addressing unmet patient needs through innovation-driven therapies. About Lupin Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with a strong presence across India, the U.S., Other Developed Markets, and Emerging Markets, with products distributed in over 100 markets. Lupin has a diversified portfolio spanning generics, complex generics, specialty medicines, and biosimilars, and continues to strengthen its market position through a differentiated portfolio. The company maintains strong leadership in the U.S. and India across core therapeutic areas, including cardiovascular, respiratory, diabetes, gastrointestinal, and women\u2019s health. 15 state-of-the-art manufacturing facilities support sustainable operations, with 6 research centers and a dedicated workforce of over 26,000 professionals. Lupin continues to expand the healthcare ecosystem through diagnostics, digital health, Page 2 of 2 BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN Press Release patient-support programs, and disease management initiatives. Sustainability continues to be a core pillar of the company\u2019s business strategy. To know more, visit www.lupin.com or follow us on LinkedIn https:\/\/www.linkedin.com\/company\/lupin For further information or queries, please contact: Rajalakshmi Azariah Vice President & Global Head \u2013 Corporate Communications, Lupin rajalakshmiazariah@lupin.com\"},{\"summary\":\"a press release dated August 06, 2026, titled \\\"Lupin Q1 FY2027 Results \\\".\",\"category\":\"Press Release\",\"date\":\"06-Aug-2026 22:04:15\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_06082026215741_SE_Intimation_Press_Release.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"a press release dated October 06, 2026, titled \\\"Lupin Launches Formoflo-G\u00ae MDI, World s First Fixed-dose Triple Combination Drug for COPD Management\\\".\",\"category\":\"Press Release\",\"date\":\"06-Oct-2026 09:38:12\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_06102026093541_SELetterpressrelease.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":4},{\"summary\":\"a press release dated September 28, 2026, titled \\\"Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension\\\".\",\"category\":\"Press Release\",\"date\":\"28-Sep-2026 09:13:36\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_28092026091311_SELetterPressRelease.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"a press release dated September 04, 2026, titled \\\"Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP\\\".\",\"category\":\"Press Release\",\"date\":\"04-Sep-2026 17:38:35\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_04092026173742_SELetterPressRelease.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3}],\"recent_news\":[{\"summary\":\"a press release dated August 06, 2026, titled \\\"Lupin Q1 FY2027 Results \\\".\",\"category\":\"Press Release\",\"date\":\"06-Aug-2026 22:04:15\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_06082026215741_SE_Intimation_Press_Release.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"a press release dated October 06, 2026, titled \\\"Lupin Launches Formoflo-G\u00ae MDI, World s First Fixed-dose Triple Combination Drug for COPD Management\\\".\",\"category\":\"Press Release\",\"date\":\"06-Oct-2026 09:38:12\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_06102026093541_SELetterpressrelease.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":4},{\"summary\":\"a press release dated September 28, 2026, titled \\\"Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension\\\".\",\"category\":\"Press Release\",\"date\":\"28-Sep-2026 09:13:36\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_28092026091311_SELetterPressRelease.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"a press release dated September 04, 2026, titled \\\"Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP\\\".\",\"category\":\"Press Release\",\"date\":\"04-Sep-2026 17:38:35\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_04092026173742_SELetterPressRelease.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3}],\"shareholding_snapshot\":{\"promoter_pct\":46.85,\"public_pct\":53.15,\"fii_pct\":22.42,\"dii_pct\":24.65,\"mf_pct\":14.84,\"institutional_pct\":47.07,\"noninst_pct\":6.08,\"mf_scheme_count\":39,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"Hdfc Trustee Company Ltd. A\/C Hdfc Balanced Advantage Fund\",\"shares\":19986840,\"pct\":4.37},{\"name\":\"Nippon Life India Trustee Ltd- A\/C Nippon India Growth Mid Cap Fund\",\"shares\":11894403,\"pct\":2.6},{\"name\":\"Sbi Elss Tax Saver Fund\",\"shares\":8958810,\"pct\":1.96},{\"name\":\"Mirae Asset Large &amp; Midcap Fund\",\"shares\":7965880,\"pct\":1.74}],\"period\":\"30-JUN-2026\",\"submission_date\":\"21-JUL-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1698021_21072026020405_WEB.xml\",\"previous_period\":\"31-MAR-2026\",\"previous_promoter_pct\":46.86,\"previous_fii_pct\":21.71,\"previous_dii_pct\":25.32,\"previous_mf_pct\":16.93,\"previous_institutional_pct\":47.03,\"previous_mf_scheme_count\":41,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"bulk_block_deals\":[{\"deal_type\":\"Block\",\"date\":\"2026-08-27T07:00:00+00:00\",\"party\":\"\",\"side\":\"Sell\",\"quantity\":\"\",\"price\":\"\",\"summary\":\"Price Action | Lupin shares slip as Citi downgrades to sell; ICICI Pru AMC slips 3% on block deal. Price Action | Lupin shares slip as Citi downgrades to sell; ICICI Pru AMC slips 3% on block deal Moneycontrol.com\",\"source\":\"Moneycontrol.com\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>LUPIN share price fell 0.81% to \u20b92,012.90 today. See why LUPIN is falling, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":4472,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"LUPIN Share Price Today: Why LUPIN Is Falling 0.81% | 7 October 2026","_witty_meta_description":"LUPIN share price fell 0.81% to \u20b92,012.90 today. See why LUPIN is falling, volume context, company developments and what to watch next.","_witty_primary_phrase":"LUPIN share price today","_witty_reason_label":"sector-aligned pullback and mild profit-taking","_witty_reason_confidence":"low","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[222],"class_list":["post-4473","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-lupin"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/4473","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=4473"}],"version-history":[{"count":7,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/4473\/revisions"}],"predecessor-version":[{"id":5240,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/4473\/revisions\/5240"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/4472"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=4473"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=4473"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=4473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}